Vaccines for the Elderly
Overview
Authors
Affiliations
Vaccination is the most efficient strategy to prevent infectious disease. The increased vulnerability to infection of the elderly makes them a particularly important target population for vaccination. However, most vaccines are less immunogenic and efficient in the elderly because of age-related changes in the immune system. Vaccination against influenza, Streptococcus pneumoniae and varicella zoster virus is recommended for the elderly in many countries. Various strategies such as the use of adjuvants and novel administration routes are pursued to improve influenza vaccination for the elderly and recent developments in the field of pneumococcal vaccination led to the licensure of protein-conjugated polysaccharide vaccines containing up to 13 serotypes. As antibody titres are generally lower in the elderly and-particularly for inactivated vaccines-decline fast in the elderly, regular booster immunizations, for example against tetanus, diphtheria and, in endemic areas, tick-borne encephalitis, are essential during adulthood to ensure protection of the elderly. With increasing health and travel opportunities in old age the importance of travel vaccines for persons over the age of 60 is growing. However, little is known about immunogenicity and efficacy of travel vaccines in this age group. Despite major advances in the field of vaccinology over the last decades, there are still possibilities for improvement concerning vaccines for the elderly. Novel approaches, such as viral vectors for antigen delivery, DNA-based vaccines and innovative adjuvants, particularly toll-like receptor agonists, will help to achieve optimal protection against infectious diseases in old age.
Wang F, Zhou L, Wagner A, Chen Z, Lu Y Vaccines (Basel). 2024; 12(10).
PMID: 39460268 PMC: 11511531. DOI: 10.3390/vaccines12101101.
Li J, Xu J, Liu Y, Chen L, Yu L, Xiao X Hum Vaccin Immunother. 2024; 20(1):2389602.
PMID: 39171541 PMC: 11346555. DOI: 10.1080/21645515.2024.2389602.
Vaccinomics and adversomics: key elements for a personalized vaccinology.
Lagana A, Visalli G, Di Pietro A, Facciola A Clin Exp Vaccine Res. 2024; 13(2):105-120.
PMID: 38752004 PMC: 11091437. DOI: 10.7774/cevr.2024.13.2.105.
Ben Hamouda W, Hanachi M, Ben Hamouda S, Kammoun Rebai W, Gharbi A, Baccouche A Trop Med Infect Dis. 2024; 9(3).
PMID: 38535885 PMC: 10975151. DOI: 10.3390/tropicalmed9030061.
Leomanni L, Collatuzzo G, Sansone E, Sala E, De Palma G, Porru S Vaccines (Basel). 2023; 11(10).
PMID: 37896931 PMC: 10610704. DOI: 10.3390/vaccines11101527.